A novel, portable device for effective, non-invasive, non-ionising and safe breast cancer detection

In 2022 2.3M people were diagnosed with breast cancer (BC), globally, with roughly 670,000 deaths. In the five-year period before this, there were 7.8M cases, making it the most prevalent cancer globally. Current breast cancer screening techniques in the UK are imperfect, expensive, painful, subject to operator variability, fail to work in dense breast tissue and emit ionising radiation. This disproportionately affects younger women, women of colour and women from impoverished backgrounds. Zedsen has created a novel scanner that will improve early cancer diagnosis, whilst reducing costs and saving lives. Zedsen aims to address these current diagnostic challenges with its non-invasive, sensing technology to detect breast cancer without emitting ionising radiation whilst being comfortable for patients. Zedsen uses its pioneering, patent-protected scanners to evaluate changes in the electrical properties of breast tissue. This has the potential to revolutionise breast cancer diagnosis by providing easy-to-understand, quantitative information to allow doctors to exclude cancer with confidence. Our mission is to improve access to cancer-care on a global level, with our first target being breast cancer. The Zedsen device has the potential to deliver diagnoses to many other cancers. We want to deliver accurate, affordable and clinically actionable healthcare to all.